These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 19709544)

  • 1. [Management of sarcoidosis-associated chronic hepatitis C virus infection: course and treatment].
    Longueira Suárez R; Ammari I; Lamas Ferreiro JL; Sopeña Pérez-Argüelles B; Martínez-Vázquez C
    Rev Clin Esp; 2009; 209(7):358-9. PubMed ID: 19709544
    [No Abstract]   [Full Text] [Related]  

  • 2. The evolving treatment of chronic hepatitis C: where we stand a decade out.
    Saadeh S; Davis GL
    Cleve Clin J Med; 2004 May; 71 Suppl 3():S3-7. PubMed ID: 15468610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapy of chronic Hepatitis C in 2008].
    Niederau C; Kaden T
    MMW Fortschr Med; 2008 Mar; 150(13):31-4. PubMed ID: 18522354
    [No Abstract]   [Full Text] [Related]  

  • 4. [Treatment of chronic hepatitis C: shorter treatment duration for genotype 2 or 3 infection].
    Jeong SH
    Korean J Hepatol; 2007 Sep; 13(3):301-3. PubMed ID: 17898546
    [No Abstract]   [Full Text] [Related]  

  • 5. [Antiviral treatments during cirrhosis].
    Bronowicki JP
    Gastroenterol Clin Biol; 2006; 30(6-7):899-902. PubMed ID: 16885876
    [No Abstract]   [Full Text] [Related]  

  • 6. [Advance in the management of the difficult-to-treat patients with chronic hepatitis C].
    Xie Y; Li MH
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):484-6. PubMed ID: 19912677
    [No Abstract]   [Full Text] [Related]  

  • 7. [Diabetes mellitus during interferon therapy].
    Tarabini-Castellani P; Apraiz L; Portu J; Agud JM
    Enferm Infecc Microbiol Clin; 2008 Feb; 26(2):120-1. PubMed ID: 18341927
    [No Abstract]   [Full Text] [Related]  

  • 8. [Antiviral treatment in liver cirrhosis due to hepatitis C virus].
    Martínez-Bauer E; Forns X
    Gastroenterol Hepatol; 2003 May; 26(5):303-6. PubMed ID: 12732104
    [No Abstract]   [Full Text] [Related]  

  • 9. [Exceptional pancytopenia secondary to treatment with pegylated interferon and ribavirin].
    Wikman Jorgensen PE; Jover Díaz FM; Cuadrado Pastor JM
    Gastroenterol Hepatol; 2007 Apr; 30(4):253. PubMed ID: 17408558
    [No Abstract]   [Full Text] [Related]  

  • 10. Impact of occult hepatitis B virus infection or hepatitis B virus DNA integration on efficacy of chronic hepatitis C treatment with peginterferon and ribavirin: where are we?
    Hu KQ; Zhang YY
    J Clin Gastroenterol; 2014 Jan; 48(1):3-5. PubMed ID: 24045272
    [No Abstract]   [Full Text] [Related]  

  • 11. Pegylated interferon (alone or with ribavirin) for chronic hepatitis C in haemodialysis population.
    Espinosa M; Hernàndez J; Arenas MD; Carnicer F; Caramelo C; Fabrizi F
    Kidney Blood Press Res; 2015; 40(3):258-65. PubMed ID: 25997572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pegylated-interferon alpha plus ribavirin-induced subacute thyroiditis in chronic hepatitis C].
    Abellán Galiana P; Pérez-Lázaro A; Aguilera Sancho-Tello V; Merino Torres JF; Berenguer Haym M; Piñón Sellés F
    Endocrinol Nutr; 2009 Mar; 56(3):136-9. PubMed ID: 19627727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment for chronic hepatitis C, more opportunity, more challenge].
    Wei L
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):481-3. PubMed ID: 19912676
    [No Abstract]   [Full Text] [Related]  

  • 14. Summaries for patients. Pegylated interferon with or without ribavirin for patients with hepatitis C receiving hemodialysis.
    Ann Intern Med; 2013 Dec; 159(11):I-14. PubMed ID: 24297207
    [No Abstract]   [Full Text] [Related]  

  • 15. PEG-IFN, RBV dosing during chronic HCV re-treatment.
    Highleyman L
    IAPAC Mon; 2007 Feb; 13(2):55. PubMed ID: 17948601
    [No Abstract]   [Full Text] [Related]  

  • 16. [Do the interferons have an antifibrotic action? The hepatologist's point of view].
    Poynard T
    Rev Med Interne; 2002 Nov; 23 Suppl 4():517s-521s. PubMed ID: 12481408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined antiviral therapy of hepatitis C virus in dialysis patients: meta-analysis of clinical trials.
    Fabrizi F; Dixit V; Martin P; Messa P
    J Viral Hepat; 2011 Jul; 18(7):e263-9. PubMed ID: 21108701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pulmonary sarcoidosis associated with pegylated interferon in the treatment of chronic hepatitis C].
    Ubiña-Aznar E; Fernández-Moreno N; Rivera-Irigoín R; Navarro-Jarabo JM; García-Fernández G; Pérez-Aisa A; Vera-Rivero F; Fernández-Pérez F; Moreno-Mejías P; Méndez-Sánchez I; de Sola-Earle C; Sánchez-Cantos A
    Gastroenterol Hepatol; 2005 Oct; 28(8):450-2. PubMed ID: 16185580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chronic hepatitis C: initial treatment in patients without previous treatment].
    Diago M
    Gastroenterol Hepatol; 2002 May; 25(5):347-55. PubMed ID: 11985813
    [No Abstract]   [Full Text] [Related]  

  • 20. Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection.
    Lagging M; Langeland N; Pedersen C; Färkkilä M; Buhl MR; Mørch K; Dhillon AP; Alsiö A; Hellstrand K; Westin J; Christensen P; Leutscher P; Norkrans G;
    Hepatology; 2008 Aug; 48(2):695. PubMed ID: 18666232
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.